Sapphire Star Partners LP trimmed its holdings in ABIOMED, Inc. (NASDAQ:ABMD) by 19.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,451 shares of the medical equipment provider’s stock after selling 841 shares during the period. Sapphire Star Partners LP’s holdings in ABIOMED were worth $582,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also made changes to their positions in ABMD. Teachers Advisors LLC lifted its position in shares of ABIOMED by 2.7% in the first quarter. Teachers Advisors LLC now owns 43,588 shares of the medical equipment provider’s stock valued at $5,457,000 after acquiring an additional 1,136 shares in the last quarter. Legal & General Group Plc lifted its position in shares of ABIOMED by 123.0% in the first quarter. Legal & General Group Plc now owns 25,379 shares of the medical equipment provider’s stock valued at $3,177,000 after acquiring an additional 13,999 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in shares of ABIOMED by 4.6% in the first quarter. Dimensional Fund Advisors LP now owns 138,140 shares of the medical equipment provider’s stock valued at $17,295,000 after acquiring an additional 6,134 shares in the last quarter. Schwab Charles Investment Management Inc. lifted its position in shares of ABIOMED by 6.6% in the first quarter. Schwab Charles Investment Management Inc. now owns 113,284 shares of the medical equipment provider’s stock valued at $14,184,000 after acquiring an additional 7,006 shares in the last quarter. Finally, State Street Corp lifted its position in shares of ABIOMED by 2.0% in the first quarter. State Street Corp now owns 1,047,258 shares of the medical equipment provider’s stock valued at $131,116,000 after acquiring an additional 20,221 shares in the last quarter. Institutional investors and hedge funds own 90.55% of the company’s stock.

Shares of ABIOMED, Inc. (NASDAQ ABMD) traded up $4.85 during mid-day trading on Friday, hitting $194.90. The stock had a trading volume of 320,337 shares, compared to its average volume of 388,284. The company has a quick ratio of 5.20, a current ratio of 5.84 and a debt-to-equity ratio of 0.02. The stock has a market capitalization of $8,617.70, a P/E ratio of 124.94, a PEG ratio of 2.60 and a beta of 0.23.

ABIOMED (NASDAQ:ABMD) last issued its earnings results on Thursday, October 26th. The medical equipment provider reported $0.54 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.38 by $0.16. ABIOMED had a return on equity of 13.89% and a net margin of 18.27%. The firm had revenue of $132.80 million for the quarter, compared to analysts’ expectations of $131.18 million. During the same period in the previous year, the firm posted $0.20 earnings per share. The business’s revenue was up 28.9% compared to the same quarter last year. research analysts expect that ABIOMED, Inc. will post 2.38 earnings per share for the current fiscal year.

In other ABIOMED news, Director Paul Thomas sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 15th. The stock was sold at an average price of $154.71, for a total transaction of $1,547,100.00. Following the sale, the director now directly owns 12,172 shares of the company’s stock, valued at $1,883,130.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Andrew J. Greenfield sold 11,282 shares of the business’s stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $169.32, for a total value of $1,910,268.24. The disclosure for this sale can be found here. Insiders sold 61,646 shares of company stock worth $10,003,780 over the last ninety days. Insiders own 7.00% of the company’s stock.

ABMD has been the topic of several research analyst reports. Morgan Stanley restated an “equal weight” rating and issued a $140.00 price objective (up from $135.00) on shares of ABIOMED in a research report on Monday, July 10th. SunTrust Banks, Inc. initiated coverage on ABIOMED in a research report on Friday, September 29th. They issued a “buy” rating and a $195.00 price objective on the stock. BTIG Research downgraded ABIOMED from a “buy” rating to a “neutral” rating in a research report on Monday, October 16th. BidaskClub downgraded ABIOMED from a “buy” rating to a “hold” rating in a research report on Saturday, August 26th. Finally, Jefferies Group LLC boosted their price objective on ABIOMED from $165.00 to $175.00 and gave the company a “buy” rating in a research report on Friday, August 4th. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. ABIOMED presently has an average rating of “Buy” and a consensus price target of $183.25.

WARNING: “ABIOMED, Inc. (ABMD) Shares Sold by Sapphire Star Partners LP” was published by Watch List News and is the sole property of of Watch List News. If you are reading this article on another publication, it was stolen and reposted in violation of United States & international copyright laws. The correct version of this article can be viewed at https://www.watchlistnews.com/abiomed-inc-abmd-shares-sold-by-sapphire-star-partners-lp/1680669.html.

ABIOMED Company Profile

ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.

Want to see what other hedge funds are holding ABMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ABIOMED, Inc. (NASDAQ:ABMD).

Institutional Ownership by Quarter for ABIOMED (NASDAQ:ABMD)

Receive News & Ratings for ABIOMED Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.